[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100548887":3},{"organization":4,"armGroups":7,"interventions":48,"overallOfficials":82,"centralContacts":86,"locations":93,"responsibleParty":140,"collaborators":91,"id":142,"slug":143,"hasResults":144,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":148,"eligibilityCriteria":149,"healthyVolunteers":144,"sex":150,"minAge":91,"maxAge":151,"enrollmentInfo":152,"targetDuration":91,"studyType":155,"phases":156,"briefSummary":158,"conditions":159,"keywords":91,"overallStatus":96,"whyStopped":91,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":170},{"fullName":5,"class":6},"University Hospital, Ghent","OTHER",[8,13,18,23,28,33,38,43],{"label":9,"type":6,"description":10,"interventionNames":11},"Amoxicillin-clavulanate","Patients receiving amoxicillin-clavulanate as part of routine clinical care. Study procedure: blood sampling",[12],"Other: Amoxicillin-clavulanate",{"label":14,"type":6,"description":15,"interventionNames":16},"Piperacillin-tazobactam","Patients receiving piperacillin-tazobactam as part of routine clinical care. Study procedure: blood sampling",[17],"Other: Piperacillin-tazobactam",{"label":19,"type":6,"description":20,"interventionNames":21},"Meropenem","Patients receiving meropenem as part of routine clinical care. Study procedure: blood sampling",[22],"Other: Meropenem",{"label":24,"type":6,"description":25,"interventionNames":26},"Cefazolin","Patients receiving cefazolin as part of routine clinical care. Study procedure: blood sampling",[27],"Other: Cefazolin",{"label":29,"type":6,"description":30,"interventionNames":31},"Vancomycin","Patients receiving vancomycin as part of routine clinical care. Study procedure: blood sampling",[32],"Other: Vancomycin",{"label":34,"type":6,"description":35,"interventionNames":36},"Teicoplanin","Patients receiving teicoplanin as part of routine clinical care. Study procedure: blood sampling",[37],"Other: Teicoplanin",{"label":39,"type":6,"description":40,"interventionNames":41},"Ciprofloxacin","Patients receiving ciprofloxacin as part of routine clinical care. Study procedure: blood sampling",[42],"Other: Ciprofloxacin",{"label":44,"type":6,"description":45,"interventionNames":46},"Amikacin","Patients receiving amikacin as part of routine clinical care. Study procedure: blood sampling",[47],"Other: Amikacin",[49,54,58,62,66,70,74,78],{"type":6,"name":9,"description":50,"armGroupLabels":51,"otherNames":52},"blood sampling in patients receiving amoxicillin-clavulanate as part of routine clinical care",[9],[53],"Blood sampling",{"type":6,"name":14,"description":55,"armGroupLabels":56,"otherNames":57},"blood sampling in patients receiving piperacillin-tazobactam as part of routine clinical care.",[14],[53],{"type":6,"name":19,"description":59,"armGroupLabels":60,"otherNames":61},"blood sampling in patients receiving meropenem as part of routine clinical care.",[19],[53],{"type":6,"name":24,"description":63,"armGroupLabels":64,"otherNames":65},"blood sampling in patients receiving cefazolin as part of routine clinical care.",[24],[53],{"type":6,"name":29,"description":67,"armGroupLabels":68,"otherNames":69},"blood sampling in patients receiving vancomycin as part of routine clinical care.",[29],[53],{"type":6,"name":34,"description":71,"armGroupLabels":72,"otherNames":73},"blood sampling in patients receiving teicoplanin as part of routine clinical care.",[34],[53],{"type":6,"name":39,"description":75,"armGroupLabels":76,"otherNames":77},"blood sampling and urine sampling in patients receiving ciprofloxacin as part of routine clinical care.",[39],[53],{"type":6,"name":44,"description":79,"armGroupLabels":80,"otherNames":81},"blood sampling in patients receiving amikacin as part of routine clinical care.",[44],[53],[83],{"name":84,"affiliation":5,"role":85},"Annick de Jaeger, MD","PRINCIPAL_INVESTIGATOR",[87],{"name":88,"role":89,"phone":90,"phoneExt":91,"email":92},"Pieter De Cock, PharmD","CONTACT","+32 9 332 29 69",null,"pieter.decock@uzgent.be",[94,115,127],{"facility":95,"status":96,"city":97,"state":98,"zip":99,"country":100,"countryCode":101,"cosmosGeoPoint":102,"geoPoint":107,"contacts":108},"Queen Fabiola Children's University Hospital","RECRUITING","Brussels","Brussels Capital","1020","Belgium","BE",{"type":103,"coordinates":104},"Point",[105,106],4.34878,50.85045,{"lat":106,"lon":105},[109,112],{"name":110,"role":89,"phone":91,"phoneExt":91,"email":111},"Biarent Dominique","dominique.biarent@huderf.be",{"name":113,"role":89,"phone":91,"phoneExt":91,"email":114},"Vens Daphne","daphnevania.vens@huderf.be",{"facility":116,"status":96,"city":117,"state":91,"zip":118,"country":100,"countryCode":101,"cosmosGeoPoint":119,"geoPoint":123,"contacts":124},"University Hospital","Ghent","9000",{"type":103,"coordinates":120},[121,122],3.71667,51.05,{"lat":122,"lon":121},[125],{"name":126,"role":89,"phone":91,"phoneExt":91,"email":92},"Pieter De Cock",{"facility":128,"status":96,"city":129,"state":91,"zip":130,"country":100,"countryCode":101,"cosmosGeoPoint":131,"geoPoint":135,"contacts":136},"Universitair hospital","Leuven","3000",{"type":103,"coordinates":132},[133,134],4.70093,50.87959,{"lat":134,"lon":133},[137],{"name":138,"role":89,"phone":91,"phoneExt":91,"email":139},"Debaveye Yves","yves.debaveye@uzleuven.be",{"type":141,"investigatorFullName":91,"investigatorTitle":91,"investigatorAffiliation":91,"oldNameTitle":91,"oldOrganization":91},"SPONSOR","100548887","pediatric-antibiotic-dosing-in-extracorporal-membrane-oxygenation-padecmo-100548887",false,"NCT06426836","Pediatric Antibiotic Dosing in Extracorporal Membrane Oxygenation (PADECMO)","Pediatric Antibiotic Dosing in Extracorporal Membrane Oxygenation","PADECMO","Inclusion Criteria:\n\n* patients admitted to the pediatric intensive care unit or cardiac intensive care unit\n* patient age : 1,8 kg-15 years\n* patient receiving antibiotic treatment (piperacillin-tazobactam, meropenem, amoxicillin-clavulanate, cephazolin, vancomycin, teicoplanin, ciprofloxacin, amikacin)\n* intra-arterial or intravenous access other than the drug infusion line available for blood sampling (arterial line is preferred)\n* extracorporeal membrane oxygenation circuit\n\nExclusion Criteria:\n\n* no catheter in place for blood sampling\n* absence of parental\u002Fpatient consent\n* known hypersensitivity to beta-lactam antibiotics and ciprofloxacin","ALL","15 Years",{"count":153,"type":154},300,"ESTIMATED","INTERVENTIONAL",[157],"NA","Pharmacokinetics of antibiotics in critically ill neonates, infants and children on extracorporeal membrane oxygenation (ECMO).",[160,9,14,19,24,34,29,39,44],"Pharmacokinetics","2026-01-15",{"date":163,"type":164},"2026-01-16","ACTUAL",{"date":166,"type":164},"2016-08-19",{"date":168,"type":154},"2026-07-01",{"name":5,"class":6},3]